Introduction
============

Delayed cervical palsy (DCP) is a recognized complication of cervical spine surgery. Although unilateral C5 paresis of the deltoid and/or biceps brachia muscles in the absence of myelopathic symptoms is the most common presentation, DCPs can also manifest bilaterally involving different and/or multiple cervical myotomes.[@JR1500120-1] Varying degrees of sensory loss and pain often accompany weakness; however, neither is a requirement for diagnosis. The reported incidence ranges from 0 to 30%,[@JR1500120-2] [@JR1500120-3] [@JR1500120-4] [@JR1500120-5] depending on the study population and procedure type, with overall mean incidence 5% via meta-analysis.[@JR1500120-4] DCPs most commonly present within the first 3 days following surgery but have been reported up to 2 months after surgery.[@JR1500120-2] [@JR1500120-6] Fortunately, the majority resolve within 6 months, though residual deficits may persist in up to 20%.[@JR1500120-2]

Despite identification of the predisposing factors and plausible theories, the true etiology remains unknown. The majority of the proposed theories can be categorized as either mechanical or vascular and include nerve root traction due to postoperative cord shift or change in alignment, spinal cord ischemia, and reperfusion injury.[@JR1500120-4] [@JR1500120-5] [@JR1500120-7] [@JR1500120-8] [@JR1500120-9] [@JR1500120-10] Excessive root traction is the most commonly cited mechanical etiology, supported by differences in preoperative foraminal width, laminectomy trough width, preexisting rotation of the spinal cord, and postlaminectomy cord drift posteriorly in patients who developed C5 palsies compared with controls. Root traction is also supported by a decreased incidence of DCPs following prophylactic foraminotomies.[@JR1500120-11] [@JR1500120-12] [@JR1500120-13] Autoimmune and inflammatory etiologies such as idiopathic brachial neuritis (Parsonage-Turner syndrome) and postsurgical inflammatory neuropathy (PSIN) have less frequently been cited but have certainly been described after cervical decompression and fusion.[@JR1500120-14] [@JR1500120-15] Other variables that have been associated with an increased incidence of DCPs include male gender and the underlying pathology (ossification of the posterior longitudinal ligament \> cervical spondylomyelopathy).[@JR1500120-6] The heterogeneity of previously established risk factors and lack of an all-encompassing theory indicate that the etiology may be multifactorial. Additionally, most previous studies focused on Asian cohorts developing DCPs following laminoplasty, specifically confined to the C5 level. Thus, the incidence in patients undergoing either laminectomy alone or cervical decompression with instrumented fusion in North American populations is not well established, as is the frequency of involvement of other cervical levels.

The present study evaluated the overall incidence of DCPs in all cervical myotomes following cervical decompression with and without instrumented fusion for degenerative disease of the cervical spine. The presence of previously established risk factors for PSIN outlined by Staff et al was also assessed relative to internal controls.[@JR1500120-15]

Materials and Methods
=====================

Selection Criteria
------------------

All aspects of this study were approved by the Institutional Review Board and in adherence with ethical standards. We retrospectively reviewed 1,768 consecutive, current procedural terminology (CPT)-coded cervical decompressions with and without instrumented fusion at Mayo Clinic Rochester between January 2008 and December 2013 for postoperative weakness within 6 weeks of the operative date. DCPs were defined as either unilateral or bilateral, new onset or worsened motor function confined to one or more cervical myotomes. Both the operative note and the immediate postoperative exam record were carefully evaluated for weakness or pain consistent with iatrogenic injury. Patients who experienced weakness directly attributable to intraoperative injury or upper extremity pain or sensory symptoms without accompanying weakness were excluded. We also excluded all tumor and trauma cases following review of all the pertinent preoperative documentation to specifically evaluate the incidence of DCPs in patients treated for degenerative disease.

Baseline Characteristics and Assessment of Risk Factors
-------------------------------------------------------

The electronic medical record of every patient was reviewed for baseline data including age, gender, and length of follow-up. DCPs were further characterized by myotomal involvement, either unilateral or bilateral, and worse/end motor grade. Finally, the presence of suggested risk factors for PSIN were recorded as outlined by Staff et al (intraoperative transfusions, history of diabetes, comorbid cancer, concomitant history of infection, and history of smoking).[@JR1500120-15] Several categorical variables were further analyzed in more specific subcategories including transfusion (intraoperative versus postoperative prior to discharge), comorbid cancer (active---metastatic disease or active tumor burden; remote---no evidence of disease), concomitant history of infection (active---current use of antibiotics or chronic infection; remote---acute infection within three months), and smoking (active---smoking within 3 months of operative date; remote---any other history). A history of autoimmune disease was also recorded as positive if the patient had a documented history of 1 or more of the 81 autoimmune diseases as reported in a recent comprehensive review by Hayter and Cook ([Appendix A](#TB1500120-1a){ref-type="table"}).[@JR1500120-16] Seronegative spondyloarthropathies (ankylosing spondylitis, reactive arthritis, and psoriatic arthritis) are notable diseases of the spine with a potential autoimmune origin excluded by Hayter and Cook and thus were evaluated as a separate variable. The history of autoimmune disease was further classified into one of four categories: diabetes mellitus type I, inflammatory bowel disease (Crohn disease, ulcerative colitis), rheumatoid arthritis, and other. Underlying ossification of the posterior longitudinal ligament was not specifically evaluated given its low incidence among our study cohort, a finding consistent with epidemiologic studies completed in North America.[@JR1500120-17] Additional analysis was performed on operative differences including approach (anterior, posterior, or both) and use of instrumentation. The intraoperative somatosensory and motor evoked potentials were reviewed when available only in patients who developed a DCP. CPT coding and chart review were used in tandem to classify procedures. When both CPT coding and reviewer classification were concordant, procedures were classified into one of several nonexclusive categories: anterior fusion, anterior diskectomy and fusion, arthroplasty, corpectomy, foraminotomy, laminectomy without fusion, laminoplasty, osteotomy, posterior fusion, and revision. Cases were included in multiple categories if applicable. Procedure categories including more than 100 cases were analyzed as a categorical variable for the entire cohort, as well as examined separately for procedure specific risk factors. Postoperative electromyograms (EMGs) within 6 months of the operative date were also evaluated for patients with persistent weakness. These studies were evaluated for bilateral involvement, multiple myotomes, and patterns consistent with a brachial plexopathy.

###### Complete list of the 81 autoimmune diseases, by selected epidemiologic and genetic characteristics

  Disorder (system)                                                                                                                              Tissue autoantibody                               Molecular target                                  Pathogenic molecular target   Females (%)   Prevalence (per 10^5^)                        Location
  ---------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ----------------------------- ------------- --------------------------------------------- ---------------------------------------------
  Autoimmune disseminated encephalomyelitis                                                                                                      Anti-myelin                                       MOG                                               Probable                      43            0.4[a](#FN1500120-2){ref-type="table-fn"}     World
  Autoimmune inner ear disease                                                                                                                   Anti-cochlear                                                                                                                     65            \<0.1                                         World
  Batten disease/neuronal ceroid lipofuscinoses                                                                                                  Anti-GAD                                          GAD65                                             Probable                      40            0.8                                           Norway
  Chronic inflammatory demyelinating polyneuropathy                                                                                              Anti-myelin                                       Myelin associated glycoprotein                    Probable                      30            1.3                                           World
  Encephalitis lethargica[b](#FN1500120-3){ref-type="table-fn"}                                                                                  Anti-streptolysin-O                                                                                                                             \<0.1                                         World
  Anti-basal ganglia                                                                                                                                                                                                                                                                                                                           
  Guillain--Barré syndrome                                                                                                                       Anti-ganglioside GM1                              PMP22                                             Possible                      43            1.3[a](#FN1500120-2){ref-type="table-fn"}     World
                                                                                                                                                 Anti-PMP22                                                                                                                                                                                    
  Hashimoto encephalopathy                                                                                                                       Anti-thyroid microsomal antibodies                TPO                                               Possible                      90            0.7                                           Italy
  Anti-TPO                                                                                                                                                                                                                                                                                                                                     
  Isaacs syndrome/acquired neuromyotonia[a](#FN1500120-2){ref-type="table-fn"}                                                                   Anti-VGKC                                         VGKC                                              Probable                                    \<0.1                                         World
  Anti-AChR                                                                                                                                                                                                                                                                                                                                    
  Miller Fisher syndrome[c](#FN1500120-4){ref-type="table-fn"}                                                                                   Anti-GQ1b                                                                                                                         43            \<0.1                                         World
  Anti-GM1                                                                                                                                                                                                                                                                                                                                     
  Anti-GD1a                                                                                                                                                                                                                                                                                                                                    
  Morvan syndrome                                                                                                                                Anti-VGKC                                         VGKC                                              Probable                      70            \<0.1                                         World
  Anti-neuronal AChR                                                                                                                                                                                                                                                                                                                           
  Multiple sclerosis[b](#FN1500120-3){ref-type="table-fn"}                                                                                       Anti-MOG                                          Multiple[d](#FN1500120-5){ref-type="table-fn"}    Probable                      64            58.3                                          World
  Anti-proteolipid protein                                                                                                                                                                                                                                                                                                                     
  Myasthenia gravis                                                                                                                              Anti-AChR                                         AChR                                              Likely                        73            5.1                                           USA
  MuSK                                                                                                                                                                                                                                                                                                                                         
  Narcolepsy                                                                                                                                     Anti-TRIB2                                        TRIB2                                             Probable                      39            30.6                                          USA
  Pediatric autoimmune neuropsychiatric disorders associated with Streptococcal infections (PANDAS)[b](#FN1500120-3){ref-type="table-fn"}        Anti-neuronal                                                                                                                     40            \<0.1                                         World
  Anti-GlcNAc                                                                                                                                                                                                                                                                                                                                  
  Anti-DNase B                                                                                                                                                                                                                                                                                                                                 
  Rasmussen encephalitis                                                                                                                         Anti-NMDA-type GluR                               NMDA-type GluR                                    Probable                                    \<0.1                                         World
  Stiff-person syndrome                                                                                                                          Anti-GAD                                          GAD2                                              Probable                      \>50          \<0.1                                         World
  Anti-amphiphysin                                                                                                                                                                                                                                                                                                                             
  Vogt--Koyanagi--Harada syndrome                                                                                                                Anti-Ku-Mel-1                                     KUMEL1                                            Probable                      65            \<0.1                                         World
  Addison disease                                                                                                                                Anti-21-hydroxylase                               CYP21A2                                           Probable                      63            14                                            World
  Anti-17 α-hydroxylase                                                                                                                                                                                                                                                                                                                        
  Anti-P450scc                                                                                                                                                                                                                                                                                                                                 
  Autoimmune hypoparathyroidism                                                                                                                  Anti-CaSR                                         Calcium sensing receptor                          Probable                      55            \<0.1                                         World
  Autoimmune hypophysitis                                                                                                                        Anti-pituitary cytosolic protein                                                                                                  90            \<0.1                                         World
  Autoimmune oophoritis                                                                                                                          Anti-OA                                                                                                                           100           \<0.1                                         World
  Anti-21OH                                                                                                                                                                                                                                                                                                                                    
  Autoimmune orchitis                                                                                                                            Anti-NASP                                         Nuclear autoantigenic sperm protein               Possible                      0             \<0.1                                         World
  Autoimmune polyglandular syndrome I (APECED, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome)                          Multiple[e](#FN1500120-6){ref-type="table-fn"}                                                                                    57            0.9                                           World
  Autoimmune polyglandular syndrome II                                                                                                           Anti-21-hydroxylase                                                                                                               75            1.7                                           USA
  Anti-17 α-hydroxylase                                                                                                                                                                                                                                                                                                                        
  Autoimmune polyglandular syndrome III                                                                                                          Multiple[f](#FN1500120-7){ref-type="table-fn"}                                                                                    83            \<0.1                                         World
  Diabetes mellitus, type 1                                                                                                                      Anti-GAD                                          Insulin/GAD65                                     Probable                      45            480                                           World[g](#FN1500120-8){ref-type="table-fn"}
  Anti-insulin                                                                                                                                                                                                                                                                                                                                 
  Anti-ICA512                                                                                                                                                                                                                                                                                                                                  
  Anti-IA-2β                                                                                                                                                                                                                                                                                                                                   
  Graves disease                                                                                                                                 TSIg                                              TSHR                                              Likely                        88            629                                           Denmark
  Anti-TBII                                                                                                                                                                                                                                                                                                                                    
  Hashimoto autoimmune thyroiditis                                                                                                               Anti-TPO                                          Thyroperoxidase                                   Probable                      95            791.7[h](#FN1500120-9){ref-type="table-fn"}   USA
  Anti-TG                                                                                                                                                                                                                                                                                                                                      
  Immunodysregulation, polyendocrinopathy, enteropathy, X-linked                                                                                                                                                                                                                   0             \<0.1                                         World
  Autoimmune hepatitis type 1                                                                                                                    Anti-smooth muscle antibody                       Asioglycoprotein receptor                         Possible                      78            16.9                                          Norway
  ANA                                                                                                                                                                                                                                                                                                                                          
  Anti-actin                                                                                                                                                                                                                                                                                                                                   
  Autoimmune hepatitis type 2                                                                                                                    Anti-LKM-1                                        CYP2D6                                            Possible                      89            3                                             World
  Anti-P-450 IID6                                                                                                                                                                                                                                                                                                                              
  Autoimmune pancreatitis                                                                                                                        Anti-lactoferrin                                  Lactoferrin                                       Unlikely                      33            0.7                                           World
  Anti-amylase α 2A                                                                                                                                                                                                                                                                                                                            
  Anti-ACA-II                                                                                                                                                                                                                                                                                                                                  
  Celiac disease                                                                                                                                 Anti-TG2                                          Tissue trans-glutaminase                          Probable                      57            750                                           USA
  Anti-gliadin                                                                                                                                                                                                                                                                                                                                 
  Crohn disease[b](#FN1500120-3){ref-type="table-fn"}                                                                                            ASCA                                                                                                                              41            25                                            World
  Pernicious anemia/atrophic gastritis                                                                                                           Anti-H/K                                          H/K ATP-ase                                       Likely                        67            150.9                                         USA
  Primary biliary cirrhosis                                                                                                                      Anti-mitochondrial antibodies                     Multiple[i](#FN1500120-10){ref-type="table-fn"}   Probable                      89            14.6                                          World
  Primary sclerosing cholangitis                                                                                                                 pANCA                                                                                                                             33            8                                             USA
  Ulcerative colitis[b](#FN1500120-3){ref-type="table-fn"}                                                                                       pANCA                                                                                                                             65            30                                            World
  Acquired hemophilia A                                                                                                                          Anti-FVIII                                        Factor VIII                                       Likely                        50            0.8                                           Wales
  Antiphospholipid syndrome                                                                                                                      Anti-cardiolipin                                  Beta2-GPI                                         Probable                      74            21.5                                          World
  Lupus anticoagulant                                                                                                                                                                                                                                                                                                                          
  Anti-b2GPI                                                                                                                                                                                                                                                                                                                                   
  Autoimmune hemolytic anemia                                                                                                                    Anti-erythrocyte I/i                              Erythrocyte I/i                                   Probable                      64            1.6                                           Norway
  Autoimmune lymphoproliferative syndrome                                                                                                        Anti-erythrocyte                                                                                                                  50            \<0.1                                         World
  Anti-neutrophil                                                                                                                                                                                                                                                                                                                              
  Autoimmune neutropenia                                                                                                                         Anti-NA1                                          B2 Integrin                                       Possible                      54            1[b](#FN1500120-3){ref-type="table-fn"}       Scotland
  Anti-NA2                                                                                                                                                                                                                                                                                                                                     
  Evans syndrome                                                                                                                                 Anti-platelet                                                                                                                     60            \<0.1                                         USA
  Anti-erythrocyte                                                                                                                                                                                                                                                                                                                             
  Felty syndrome                                                                                                                                 Anti-G-CSF                                        G-CSF                                             Possible                      75            1.7                                           USA
  Immune thrombocytopenic purpura                                                                                                                Anti-GpIIb/IIIa                                   Glycoprotein IIb/IIIa                             Probable                      70            72                                            Denmark
  Anti-ADAMTS13                                                                                                                                                                                                                                                                                                                                
  Anti-glycoprotein Ib-IX                                                                                                                                                                                                                                                                                                                      
  Polymyositis/dermatomyositis                                                                                                                   Anti-Jo1                                          Multiple[j](#FN1500120-11){ref-type="table-fn"}   Probable                      67            5.1                                           USA
  Anti-Mi-2                                                                                                                                                                                                                                                                                                                                    
  Anti-CADM140                                                                                                                                                                                                                                                                                                                                 
  Relapsing polychondritis                                                                                                                       Anti-collagen II                                  Collagen II                                       Probable                      66            0.4[a](#FN1500120-2){ref-type="table-fn"}     USA
  Anti-collagen IV                                                                                                                                                                                                                                                                                                                             
  Anti-collagen IX                                                                                                                                                                                                                                                                                                                             
  Rheumatoid arthritis                                                                                                                           Rheumatoid factor                                 Fibrinogen, βα                                    Probable                      75            860[h](#FN1500120-9){ref-type="table-fn"}     USA
  Anti-CCP                                                                                                                                                                                                                                                                                                                                     
  Anti-collagen II                                                                                                                                                                                                                                                                                                                             
  Still disease[b](#FN1500120-3){ref-type="table-fn"}                                                                                            ANA                                                                                                                               62            4                                             World
  Anti-endothelial cell antibodies                                                                                                                                                                                                                                                                                                             
  Erythema elevatum diutinum[b](#FN1500120-3){ref-type="table-fn"}                                                                               IgA ANCA                                                                                                                          50            \< 0.1                                        World
  Kawasaki disease[b](#FN1500120-3){ref-type="table-fn"}                                                                                                                                                                                                                           40            10[a](#FN1500120-2){ref-type="table-fn"}      USA
  Microscopic polyangiitis                                                                                                                       pANCA                                             Myeloperoxidase                                   Probable                      50            2                                             World
  Polyarteritis nodosa[b](#FN1500120-3){ref-type="table-fn"}                                                                                     Anti-endothelial cell antibodies                                                                                                  33            6.3                                           World
  Rheumatic fever                                                                                                                                Anti-streptolysin O                               Cardiac myosin                                    Likely                        50            250                                           World
                                                                                                                                                 Anti-DNase B                                                                                                                                                                                  
  Takayasu arteritis[b](#FN1500120-3){ref-type="table-fn"}                                                                                                                                                                                                                         85            0.3[a](#FN1500120-2){ref-type="table-fn"}     USA
  Temporal arteritis[b](#FN1500120-3){ref-type="table-fn"}                                                                                                                                                                                                                         85            30                                            USA
  Wegener\'s granulomatosis                                                                                                                      cANCA                                             Proteinase 3                                      Probable                      43            3                                             World
  Alopecia areata                                                                                                                                Anti-hair follicle antibodies                     Trichohyalin                                      Possible                      50            150                                           World
  Bullous pemphigoid                                                                                                                             Anti-BP180                                        Bullous pemphigoid associated glycoprotein 1      Likely                        50            1                                             World
  Cicatricial pemphigoid                                                                                                                         Anti-BP230                                        Laminin-332                                       Likely                        75            0.1                                           World
  Dermatitis herpetiformis                                                                                                                       Anti-TGase3                                       Transglutaminase                                  Probable                      36            11.2                                          USA
  Discoid lupus erythematosus                                                                                                                                                                                                                                                      66            7.3                                           World
  Epidermolysis bullosa acquisita                                                                                                                Anti-type VII collagen                            Type VII collagen                                 Likely                        58            0.2[a](#FN1500120-2){ref-type="table-fn"}     France
  Anti-plectin                                                                                                                                                                                                                                                                                                                                 
  Linear morphea                                                                                                                                 Anti-P80 Coilin                                   P80 Coilin                                        Probable                      75            1                                             World
  Pemphigus foliaceus                                                                                                                            Anti-Desmoglein I                                 Desmoglein I                                      Probable                      50            0.1[a](#FN1500120-2){ref-type="table-fn"}     World
  Pemphigus vulgaris                                                                                                                             Anti-Desmoglein III                               Desmoglein III                                    Probable                      60            0.5[a](#FN1500120-2){ref-type="table-fn"}     World
  Vitiligo                                                                                                                                       Anti-MCHR1                                        SOX10                                             Possible                      52            400.2                                         World
  Anti-SOX-10                                                                                                                                                                                                                                                                                                                                  
  Behçet disease[b](#FN1500120-3){ref-type="table-fn"}                                                                                           Anti-oral mucous membrane                                                                                                         50            1.2                                           World
  Churg--Strauss syndrome[b](#FN1500120-3){ref-type="table-fn"}                                                                                  cANCA                                                                                                                             43            0.2                                           World
  Cogan syndrome[b](#FN1500120-3){ref-type="table-fn"}                                                                                                                                                                                                                             60            \<0.1                                         World
  Calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia (CREST) syndrome                                     Anti-centromere                                                                                                                   82            5.6                                           USA
  Anti-fibrillarin                                                                                                                                                                                                                                                                                                                             
  Essential mixed cryoglobulinemia[b](#FN1500120-3){ref-type="table-fn"}                                                                         Anti-IgG                                                                                                                          75            1                                             USA
  AECA                                                                                                                                                                                                                                                                                                                                         
  Mixed connective tissue disease                                                                                                                Anti-U1-ribonucleoprotein                         SNRNP70                                                                         80            2.7                                           Japan
  Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome[b](#FN1500120-3){ref-type="table-fn"}   Anti-MAG                                                                                                                          70            \< 0.1                                        World
  Anti-GM1                                                                                                                                                                                                                                                                                                                                     
  Scleroderma                                                                                                                                    Multiple[k](#FN1500120-12){ref-type="table-fn"}   Multiple[l](#FN1500120-13){ref-type="table-fn"}   Possible                      92            24                                            World
  Sjögren syndrome                                                                                                                               ANA                                               Multiple[m](#FN1500120-14){ref-type="table-fn"}   Possible                      94            14.4                                          USA
  SSB                                                                                                                                                                                                                                                                                                                                          
  SSA                                                                                                                                                                                                                                                                                                                                          
  Systemic lupus erythematosus                                                                                                                   Multiple[n](#FN1500120-15){ref-type="table-fn"}   Multiple[o](#FN1500120-16){ref-type="table-fn"}   Possible                      88            32                                            World
  HLA-B27-associated acute anterior uveitis                                                                                                      Anti-S-antigen                                    S-antigen                                         Possible                      34            8.7[a](#FN1500120-2){ref-type="table-fn"}     World
  Sympathetic ophthalmia                                                                                                                                                                                                                                                           50            9                                             World
  Goodpasture disease                                                                                                                            Anti-basement membrane                            α3(IV)NC1 collagen                                Likely                        25            0.5                                           World

Reprinted from Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmunity Reviews 2012;11:754--765, with permission from Elsevier.[@JR1500120-16]

Incidence data (no prevalence studies identified).

Autoimmune etiology is not well established.

Generally regarded as a subset of Guillain-Barré syndrome.

Proteolipid protein, myelin oligodendrocyte glycoprotein, myelin basic protein, neurofilament light polypeptide.

Anti-candidal enolase, anti-pituitary, anti-calcium sensing receptor protein, anti-aromatic L-amino acid decarboxylase, anti-tyrosine hydroxylase.

Anti-21-hydroxylase, anti-17 α-hydroxylase, anti-thyroperoxidase.

World prevalence is difficult as disease displays latitude dependence.

Population limited to adults (over 18 years).

Seventy-four kilodalton E2, keratin, sp100, actin.

Histidyl tRNA, aminoacyl tRNA synthetase, DNA-dependent nucleosome-stimulated ATPase, EXOSC10 protein, chromodomain-helicase-DNA-binding protein 4.

Anti-Scl70,anti-PM/Scl, anti-RNA polymerase III, anti-centromere.

Topoisomerase I, Ro, La, Ku, fibrillarin.

Ro, La, golgin.

Anti-dsDNA, Anti-U1A, Anti-U2B, Anti-PCNA, Anti-Smith, Anti-SSA, Anti-SSB.

U2 snRNP B, cardiolipin, fibronectin, Ro, La, histone H2A H2B, vimentin.

Statistical Analysis
--------------------

All statistical analysis was performed with JMP 10 (SAS Institute Inc., Cary, North Carolina, United States) in consultation with an institutional biostatistician. For patients undergoing multiple procedures during the period, only the first event was analyzed to exclude bias introduced by multiple representations of patient-specific factors on statistical analysis. Univariate and multivariate analyses were performed using a nominal logistical regression and likelihood ratios. The backward selection method was utilized for the multivariate analysis, retaining each variable significant on univariate analysis. A *p* value \<0.05 was the threshold for statistical significance.

Results
=======

There were 1,669 patients who underwent 1,768 procedures during the study period, with DCPs following the initial procedure in 56 individuals (3.4%). The majority of DCPs presented in the first 72 hours following surgery (87.5%) with maximal deficit occurring within 72 hours of onset (85.7%). The C5 myotome was involved in 40 (71.4%) cases, and 31 (55.4%) cases had multiple myotomes involved. A complete analysis of temporal profile and myotomal involvement is available in [Table 1](#TB1500120-1){ref-type="table"}. There was bilateral involvement reported in 10 (17.9%) cases. Of note, 5 (8.9%) cases of DCPs occurred at levels not operated upon. Of these first operations, there were 842 (50.4%) cervical decompressions with fusion and 827 (49.6%) cervical decompressions only. In addition to the procedure categories analyzed in [Table 2](#TB1500120-2){ref-type="table"}, a minority of patients underwent arthroplasty (*n* = 6), laminoplasty (*n* = 6), osteotomy (*n* = 1), or revision (*n* = 21). The analysis of demographics and the risk factors for PSIN are also summarized in [Table 2](#TB1500120-2){ref-type="table"}.

###### Characteristics of delayed cervical palsies

  Characteristic                                                   Value
  ---------------------------------------------------------------- -----------------
  Temporal profile                                                 
   Median days to onset of symptoms ± SD, *n* (range)              1 (0--14)
   Median days to maximal neurologic deficit, *n* ± SD (range)     2 ± 6.8 (0--38)
  Myotomal involvement                                             
   Nerve root, *n* (%) of patients with delayed cervical palsies   
    C5                                                             40 (71.4%)
    C6                                                             12 (21.4%)
    C7                                                             20 (35.7%)
    C8                                                             13 (23.2%)
    T1                                                             3 (5.6%)

Abbreviation: SD, standard deviation.

###### Entire cohort demographics and likelihood ratio test *p* values on univariate analysis

                                           Positive delayed cervical palsy   Negative delayed cervical palsy   Combined            Likelihood ratio test *p* value
  ---------------------------------------- --------------------------------- --------------------------------- ------------------- -------------------------------------------------
  Number of patients                       56 (3.4%)                         1,613                             1,669               
  Male/female, *n* (% male)                37/19 (66.1%)                     999/614 (61.9%)                   1,036/633 (62.1%)   0.5275
  Age ± SD                                 62.2 ± 11.8                       57.1 ± 13.7                       57.3 ± 13.7         0.0061[a](#FN1500120-19){ref-type="table-fn"}
  Procedure                                                                                                                        
   Anterior fusion                         13 (2.6%)                         483                               496 (29.7%)         0.2676
   With diskectomy                         3 (1.7%)                          171                               174 (10.4%)         0.1689
   Posterior fusion                        27 (7.1%)                         355                               382 (22.8%)         \<0.0001[a](#FN1500120-19){ref-type="table-fn"}
   Corpectomy                              5 (4.9%)                          97                                102 (6.1%)          0.3992
   Foraminotomy                            24 (3.5%)                         653                               677 (40.6%)         0.7228
   Laminectomy (without fusion)            7 (2.6%)                          265                               272 (16.3%)         0.4184
   Sitting                                 4 (1.1%)                          348                               352 (21.1%)         0.0036[a](#FN1500120-19){ref-type="table-fn"}
  Approach                                                                                                                         0.0554
   Anterior                                10 (2.0%)                         482                               492 (29.5%)         
   Posterior                               42 (3.7%)                         1083                              1125 (67.4%)        
   Both                                    4 (7.7%)                          48                                52 (3.1%)           
  Number of operative levels                                                                                                       \<0.0001[a](#FN1500120-19){ref-type="table-fn"}
   1                                       9 (1.2%)                          721                               730 (43.7%)         
   2                                       11 (2.9%)                         363                               374 (22.4%)         
   3                                       12 (5.0%)                         230                               242 (14.5%)         
   4                                       11 (6.9%)                         148                               159 (9.5%)          
   5                                       2 (3.0%)                          64                                66 (4.0%)           
   6                                       3 (9.4%)                          29                                32 (1.9%)           
   7+                                      8 (12.1%)                         58                                66 (4.0%)           
  Previous cervical spine surgery          12 (5.0%)                         226                               238 (14.3%)         0.1404
  Transfusion                              10 (6.2%)                         151                               161 (9.6%)          0.0543
   Intraoperative                          9 (7.4%)                          112                               121 (7.2%)          0.0231[a](#FN1500120-19){ref-type="table-fn"}
   Postoperative                           4 (5.7%)                          66                                70 (4.2%)           0.3054
  Cancer                                   9 (4.3%)                          199                               208 (12.5%)         0.4225
   Active                                  0 (0%)                            47                                47 (2.8%)           0.0712
   Remote                                  9 (5.6%)                          152                               161 (9.6%)          0.1255
  History of smoking                       22 (3.3%)                         635                               657 (39.4%)         0.9902
   Active                                  8 (2.8%)                          275                               283 (17.0%)         0.5799
   Remote                                  14 (3.7%)                         360                               374 (22.4%)         0.6404
  Infection                                1 (2.2%)                          45                                46 (2.8%)           0.6307
   Active                                  1 (4.0%)                          24                                25 (1.5%)           0.8609
   Remote                                  0 (0%)                            21                                21 (1.3%)           0.2297
  Diabetes mellitus                        10 (4.1%)                         236                               246 (14.7%)         0.5142
   Type I                                  0 (0%)                            23                                23 (1.4%)           0.2086
   Type II                                 10 (8.5%)                         213                               223 (13.4%)         0.3342
  Seronegative spondylotic arthropathies   0 (0%)                            14                                14 (0.8%)           0.3273
  History of autoimmune disease            7 (5.1%)                          130                               137 (8.2%)          0.2648
   Rheumatoid arthritis                    1 (2.3%)                          42                                43 (2.6%)           0.6884
   Inflammatory bowel disease              0 (0%)                            20                                20 (1.2%)           0.2412
   Diabetes mellitus (type I)              0 (0%)                            23                                23 (1.4%)           0.2086
   Other                                   6 (10.9%)                         49                                55 (3.3%)           0.0107[a](#FN1500120-19){ref-type="table-fn"}

Abbreviation: SD, standard deviation.

*p* \< 0.05.

We found significant associations between the incidence of DCP with age (positive DCP: 62.2 versus negative DCP: 57.1, *p* = 0.0061), intraoperative transfusion (positive DCP: 16.1% versus negative DCP: 6.9%, *p* = 0.0231), and history of other autoimmune disease (positive DCP: 10.7% versus negative DCP: 3.0%, *p* = 0.0107). Significant procedural factors included posterior fusion (positive DCP: 48.2% versus negative DCP: 22.0%, *p* \< 0.0001), sitting (positive DCP: 7.0% versus negative DCP: 21.2%, *p* = 0.0037), and number of levels (positive DCP mean: 3.52 versus negative DCP: 2.26, *p* \< 0.0001). [Table 3](#TB1500120-3){ref-type="table"} summarizes the significant variables identified on univariate and multivariate analysis as well as provides a calculated odds ratio for each associated risk factor. On multivariate analysis, the number of operative levels (*p* = 0.0053, odds ratio \[OR\] = 1.27, 95% confidence interval \[CI\] 1.075 to 1.496) and nonspecific autoimmune disease (*p* = 0.0416, OR 2.95, 95% CI 1.047 to 7.092) remained significant.

###### Univariate logistic regression and multivariate logistic regression for significant risk factors for entire cohort

                                        Univariate analysis   Multivariate analysis                                                                           
  ------------------------------------- --------------------- ----------------------- ------------------------------------------------- ------ -------------- -----------------------------------------------
  Age (per year)                        1.07                  1.008--1.050            0.0061[a](#FN1500120-21){ref-type="table-fn"}     1.01   0.993--1.037   0.1815
  History of other autoimmune disease   3.83                  1.418--8.730            0.0107[a](#FN1500120-21){ref-type="table-fn"}     2.95   1.047--7.092   0.0416[a](#FN1500120-21){ref-type="table-fn"}
  Intraoperative transfusion            2.57                  1.152--5.132            0.0231[a](#FN1500120-21){ref-type="table-fn"}     0.85   0.346--1.890   0.6966
  Number of levels (per level)          1.42                  1.247--1.605            \<0.0001[a](#FN1500120-21){ref-type="table-fn"}   1.27   1.075--1.496   0.0053[a](#FN1500120-21){ref-type="table-fn"}
  Posterior fusion                      3.30                  1.920--5.653            \<0.0001[a](#FN1500120-21){ref-type="table-fn"}   1.54   0.781--3.020   0.2133
  Sitting                               0.28                  0.084--0.689            0.0036[a](#FN1500120-21){ref-type="table-fn"}     0.42   0.123--1.103   0.0816

Abbreviations: CI, confidence interval; OR, odds ratio.

*p* \< 0.05.

[Table 4](#TB1500120-4){ref-type="table"} summarizes the risk factors for specific procedure categories with a sufficient number of cases for analysis. The risk factors identified for the entire cohort were not significant for anterior diskectomy and fusion or corpectomy. Anterior fusions (number of levels, intraoperative transfusion), posterior fusions (number of levels), foraminotomies (age, sitting, number of levels, other autoimmune disease), laminectomies without fusion (author autoimmune disease), and all nonfusion procedures (sitting, other autoimmune disease) had at least one significantly correlated risk factor.

###### Significant risk factors for specific procedure categories

                                Anterior fusion                                 Anterior diskectomy and fusion   Posterior fusion                                Corpectomy   Foraminotomy                                    Laminectomy without fusion                      Nonfusion (all)                                 Entire cohort
  ----------------------------- ----------------------------------------------- -------------------------------- ----------------------------------------------- ------------ ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- -------------------------------------------------
  *n*                           496                                             174                              382                                             102          677                                             272                                             827                                             1,669[b](#FN1500120-24){ref-type="table-fn"}
  DCP incidence (%)             2.6                                             1.7                              7.1                                             4.9          3.5                                             2.5                                             2.4                                             3.4%
  Risk factors (*p* values)                                                                                                                                                                                                                                                                                                   
   Age                          0.2421                                          0.7626                           0.1474                                          0.3994       0.0228[a](#FN1500120-23){ref-type="table-fn"}   0.4378                                          0.2002                                          0.0061[a](#FN1500120-23){ref-type="table-fn"}
   Sitting                      --                                              --                               --                                              --           0.0009[a](#FN1500120-23){ref-type="table-fn"}   0.5206                                          0.0308[a](#FN1500120-23){ref-type="table-fn"}   0.0036[a](#FN1500120-23){ref-type="table-fn"}
   Number of levels             0.0082[a](#FN1500120-23){ref-type="table-fn"}   0.1290                           0.0188[a](#FN1500120-23){ref-type="table-fn"}   0.2089       0.0002[a](#FN1500120-23){ref-type="table-fn"}   0.4975                                          0.0501                                          \<0.0001[a](#FN1500120-23){ref-type="table-fn"}
   Intraoperative transfusion   0.0204[a](#FN1500120-23){ref-type="table-fn"}   0.7075                           0.9700                                          0.1772       0.1128                                          0.2975                                          0.1514                                          0.0231[a](#FN1500120-23){ref-type="table-fn"}
   Autoimmune other             0.4860                                          0.6449                           0.4289                                          0.5218       0.0038[a](#FN1500120-23){ref-type="table-fn"}   0.0184[a](#FN1500120-23){ref-type="table-fn"}   0.0018[a](#FN1500120-23){ref-type="table-fn"}   0.0107[a](#FN1500120-23){ref-type="table-fn"}

Abbreviation: DCP, delayed cervical palsy.

*p* \< 0.05.

Several cases are included in more than one procedure category.

Foraminotomies were performed in 677 cases and a DCP occurred in 24 individuals (3.5%) and at one of the roots expressly decompressed in 18 cases (2.7%). Comparing those not undergoing a foraminotomy to those who did, there was no significant difference in the rate of a DCP. Chi-square analysis was done both including cases occurring at a root not decompressed with a foraminotomy (Fisher exact test *p* = 0.78) and excluding cases where a DCP occurred at a root not decompressed with a foraminotomy (Fisher exact test *p* = 0.56).

Intraoperative monitoring of somatosensory and motor evoked potentials were reviewable for 13 individuals. Only one patient exhibited any abnormality during the procedure, but the motor evoked potential instability was not consistent with the myotome affected postoperatively. EMG results were available for 17 patients (30%) postoperatively ([Table 5](#TB1500120-5){ref-type="table"}). The incidence of bilateral (24%) and multilevel level (88%) involvement was increased when compared with clinician evaluation consistent with the DCP. Additionally, 5 (29%) were consistent with a brachial plexopathy and less indicative of a process occurring at the nerve root.

###### Postoperative electromyography characteristics in patients developing delayed cervical palsies

  Characteristic                                *n* (%)
  --------------------------------------------- ------------
  EMG within 6 mo                               17 (30.4%)
  Bilateral involvement                         4 (23.5%)
  Multilevel                                    15 (88.2%)
  Pattern consistent with brachial plexopathy   5 (29.4%)

Abbreviation: EMG, electromyogram.

The median neurologic follow-up for our cohort is 15.6 months (range 0.1 to 65.84 months). Unfortunately, there has been no recovery of motor function in 4 (7.1%) patients. However, for those with documented improvement, the first increases in motor grade were observed a median of 22.5 days postoperatively (range, 1 to 424). At last follow-up, the majority of individuals had regained normal (*n* = 27, 48.2%) or near normal (*n* = 12, 21.4%) strength.

Discussion
==========

Postoperative DCP is a known complication of cervical spine surgery with a reported incidence around 5% based on a recent meta-analysis.[@JR1500120-4] In the current study, we demonstrated that DCP occurred in 3.4% of our cohort, and the majority of these cases involved the C5 myotome. Just greater than half of cases included multiple myotomes, and 18% were bilateral. Although abnormal transcranial electrical stimulation-induced evoked potentials are highly sensitive and specific for radiculopathy that manifests immediately upon waking from anesthesia, DCP injury does not exhibit any signs of a potentially injurious event.[@JR1500120-18] Although nerve root irritation remains a possible consideration, our limited intraoperative monitoring results support the suggestion that these palsies were not likely the result of intraoperative trauma or positioning. At final follow-up, 7% had stable or worsening weakness. The rate of improvement reported in our cohort is slightly better than the 80% noted in the literature,[@JR1500120-4] though likely attributable to variability in follow-up and the definition of *improvement*.

Some authors have suggested prophylactic foraminotomies may lead to decreased rates of DCP, particularly after laminoplasty.[@JR1500120-3] [@JR1500120-19] [@JR1500120-20] Although we were unable to determine whether a foraminotomy was prophylactic from a retrospective review of operative reports, the rate of DCP at nerve roots decompressed with foraminotomies was not statistically different from those not operated upon. In fact, there was a slight trend toward an increased prevalence of DCP when a foraminotomy was performed. Although the protective effect of prophylactic foraminotomies would be better studied prospectively, this difference may suggest that the benefit of foraminotomy noted following laminoplasty in Asian cohorts may not be applicable to North American populations undergoing laminectomy and fusion.

Interestingly, none of the risk factors for PSIN as suggested by Staff et al were correlated with the development of a DCP[@JR1500120-15]; however, nonspecific autoimmune disease remained statistically significant on multivariate analysis (*p* = 0.0416). This finding, in addition to the clinical presence of bilateral (18%) and multilevel (55%) involvement and involvement of roots that were not at the operative levels (9%), suggests that autoimmune reactions or nonmechanical factors potentially play a role. Further consideration of the EMG results suggest that the reported incidences of bilaterality and multilevel involvement may be underestimated. However, the higher rates of bilateral and multimyotomal palsies observed in this subpopulation may be the result of more significant or prolonged disease requiring nerve conduction studies for further evaluation. The present study also identified increased age to be significantly correlated with the development of a DCP, which is consistent with a large series by Nassr et al, which reports an association with age and C5 palsy after corpectomy and laminoplasty.[@JR1500120-2]

We also describe several procedural risk factors that are correlated with an increased rate of DCPs on univariate analysis including posterior fusions (*p* \< 0.0001), prone versus sitting (0.0036), and number of operative levels (*p* \< 0.0001). Recently, the development of DCPs was reported by Yamanaka et al to be higher in patients undergoing instrumented fusion after cervical laminoplasty,[@JR1500120-21] a finding that was replicated in this study. Although the difference in cases selected for anterior and sitting approaches may explain this finding, another potential explanation is that the anterior approach and the sitting/semisitting position could offer some anatomical advantage or minimizes manipulation of the nerve roots. Other studies have suggested that the correction of cervical lordosis that is targeted following laminectomy and fusion can close the foramen and exacerbate the compression of the C5 root in cases of preexisting foraminal stenosis.[@JR1500120-6] It may be possible to evaluate potential differences in positioning with an anatomic study, but a complete understanding of this finding may prove elusive. The number of operative levels was extremely significant on univariate analysis (*p* \< 0.0001) and the only mechanical variable that remained significant on multivariate analysis (0.0053). This result suggests that the extent of the operation is the primary risk factor for this complication, and supports the theory that mechanical factors significantly contribute to the development of this complication.

Specifying risk factors by procedure categories further elucidates evidence regarding the etiology of risk factors. The prevalence of DCP across procedure categories in the present study is similar to values reported previously and suggests that the highest prevalence of DCP is observed during posterior fusion.[@JR1500120-6] Again, the number of operative levels appears as the dominant risk factor for both anterior and posterior fusions, which may be the result of increased traction on the nerve roots from changes in alignment/cord position and higher rates of transfusion. There is also evidence from Odate et al suggesting that one can reduce the incidence of DCPs in anterior cervical decompression and fusion cases by restricting the decompression to 15 mm and avoiding asymmetric decompressions.[@JR1500120-22] Interestingly, sitting was correlated with a lower incidence for all nonfusion cases. Due to the limited applicability of the sitting position for anterior and instrumented cases, there was a valid concern that sitting may be a proxy variable for posterior noninstrumented cases; however, the result of this study validates that sitting may be protective for this complication. The most interesting outcome of this section is the strong correlations of nonspecific autoimmune disease and age with foraminotomies. The development of a DCP seems to correlate with those undergoing direct manipulation of the nerve root in those with preexisting autoimmune disease. Although it is purely conjecture, manipulation of the nerve roots may expose immune-privileged antigens, which could further propagate an autoimmune response in an individual with heightened immunity. The bilateral and multiple myotomal presentation as well as EMG findings supporting plexopathy in some patients lend further support to this hypothesis. Further evaluation in larger cohorts may be appropriately powered to more specifically evaluate this general result.

Although there is significant evidence for a multifactorial etiology, this study identifies the number of operative levels as the most specific etiologic factor. Age and history of nonspecific autoimmune disease are identified as risk factors for this complication, which could be useful when selecting patients for surgery and counseling them as to the risks of the procedure. From a surgical perspective, the association of extent of surgery with development of DCP may lead the surgeon to be more conservative with the decompression to decrease the risk of this complication; however, this risk must be weighed against the risk of inadequate decompression resulting in continued symptoms postoperatively. Additionally, the positioning concerns may lead to specific planning considerations to minimize risk. Finally, this study is important because it represents a Western cohort of patients undergoing cervical decompression with or without fusion. Many previous studies have focused on Asian cohorts undergoing laminoplasty operations, with only C5 myotomes.

This study is limited by its retrospective design, study population, methodology, and inclusion criteria. Although verifying procedure specifics with both CPT codes and independent chart review increases our confidence in the data set, each method has its own inherent limitations that do not disappear when they are combined. The chosen study cohort also may prevent the broad applicability of this study\'s results, as nearly all of the cases were originally indicated for the treatment of degenerative spine disease. This cohort is only a segment of the larger cervical spine surgery population, and the current study does not sufficiently evaluate the potentially important variable of the original underlying pathology. Additionally, in an attempt to identify all atypical DCPs, it was necessary to use rather loose exclusion criteria. Neurologic deterioration resulting from a myelopathy or exacerbation of the original pathology could present similarly to a multimyotomal DCP. Each misclassification of other similar pathologies weakens the results and conclusions of the present study. There has also been increasing evidence that radiographic measurements including anteroposterior diameter, foramina diameter, and/or cord--lamina angle can be predictive of DCPs. These and other radiographic measurements should continue to be evaluated in similar cohorts to identify predicative factors that could be easily applied to clinical practice.[@JR1500120-23]

Conclusion
==========

The incidence of DCP is higher in patients undergoing more extensive procedures. Although a mechanical etiology is partially supported as a cause for DCP, notable correlations with autoimmune risk factors as well as bilateral and multimyotomal involvement does support the hypothesis that some DCPs may result from an autoimmune response. The present series suggests that the etiology of DCPs is multifactorial.
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